Filing Details
- Accession Number:
- 0000805928-24-000051
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-25 21:43:38
- Reporting Period:
- 2024-03-16
- Accepted Time:
- 2024-03-25 21:43:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
805928 | Axogen Inc. | AXGN | Electromedical & Electrotherapeutic Apparatus (3845) | 411301878 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1530968 | L. Karen Zaderej | 13631 Progress Boulevard Suite 400 Alachua FL 32615 | Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-03-16 | 84,847 | $0.00 | 1,157,593 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-03-21 | 33,028 | $7.68 | 1,124,565 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-03-16 | 12,500 | $0.00 | 1,137,065 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-03-21 | 3,086 | $7.68 | 1,133,979 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-03-16 | 12,975 | $0.00 | 1,146,954 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-03-21 | 3,166 | $7.68 | 1,143,788 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2024-03-16 | 84,847 | $0.00 | 84,847 | $0.00 |
Common Stock | Restricted Stock Units | Disposition | 2024-03-16 | 12,500 | $0.00 | 12,500 | $0.00 |
Common Stock | Restricted Stock Units | Disposition | 2024-03-16 | 12,975 | $0.00 | 12,975 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
84,847 | No | 4 | M | Direct | ||
12,500 | No | 4 | M | Direct | ||
0 | No | 4 | M | Direct |
Footnotes
- This reflects the number of restricted stock units that became vested as of March 16, 2024..
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
- All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
- All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.